Literature DB >> 30220340

Copper as the most likely pathogenic divergence factor between lung fibrosis and emphysema.

Rob Janssen1, Bart de Brouwer2, Jan H von der Thüsen3, Emiel F M Wouters4.   

Abstract

Although fibrosis and emphysema are in many ways on opposite ends of the pulmonary parenchymal disease spectrum, they seem to share common pathomechanistic steps. This is illustrated by the coexistence of both entities in lungs of individuals with combined pulmonary fibrosis and emphysema. Macroproteins elastin and collagen are major constituents of the pulmonary extracellular matrix. The prevailing paradigm states that emphysema is caused by an imbalance between destructive proteolytic and protective antiproteolytic enzymes leading to accelerated degradation of elastin fibers in the lungs. Rates of elastin breakdown, however, are equally enhanced in patients with idiopathic pulmonary fibrosis (IPF) and emphysema. Excessive accumulation of collagen is a hallmark of IPF. Surprisingly, collagen levels in the lung parenchyma of patients with emphysema are also higher than in controls. The concentration of elastin fibers is elevated in fibrotic lungs, despite accelerated elastinolysis, suggesting that elastin repair is also enhanced in IPF. Since elastin concentrations are reduced in emphysematous lungs, the factor of divergence between emphysema and fibrosis seems to be the degree of elastin repair. Multiple elastin repair steps can be deduced of which tropoelastin synthesis and crosslinking of tropoelastin polymers by the copper dependent enzyme lysyl oxidase seem to be the most important ones. We suspect that the distinction in the pathogeneses of lung fibrosis and emphysema depends on the local availability of copper to activate sufficient lysyl oxidase for elastin crosslinking, and suggest assessing the effects of inhalation therapy with copper plus heparin in emphysema and heparin monotherapy in IPF.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30220340     DOI: 10.1016/j.mehy.2018.08.003

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

Review 1.  Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.

Authors:  Claire Healy; Natalia Munoz-Wolf; Janné Strydom; Lynne Faherty; Niamh C Williams; Sarah Kenny; Seamas C Donnelly; Suzanne M Cloonan
Journal:  Respir Res       Date:  2021-04-29

Review 2.  Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications.

Authors:  Grażyna Gromadzka; Beata Tarnacka; Anna Flaga; Agata Adamczyk
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

3.  Pathological investigations and correlation research of microfibrillar-associated protein 4 and tropoelastin in oral submucous fibrosis.

Authors:  Binjie Liu; Wenqun Gou; Hui Feng
Journal:  BMC Oral Health       Date:  2021-11-19       Impact factor: 2.757

4.  The Relationship between Metal Exposure and Chronic Obstructive Pulmonary Disease in the General US Population: NHANES 2015-2016.

Authors:  Qiaoyuan Fei; Xueqiong Weng; Kun Liu; Shan Liu; Jingmin Chen; Xinrong Guo; Chunxia Jing
Journal:  Int J Environ Res Public Health       Date:  2022-02-13       Impact factor: 3.390

5.  Melatonin ameliorates chronic copper-induced lung injury.

Authors:  Sachin Gaun; Syed Afroz Ali; Pooja Singh; Jayant Patwa; Swaran Jeet Singh Flora; Ashok Kumar Datusalia
Journal:  Environ Sci Pollut Res Int       Date:  2022-03-31       Impact factor: 4.223

Review 6.  Current Biomedical Use of Copper Chelation Therapy.

Authors:  Silvia Baldari; Giuliana Di Rocco; Gabriele Toietta
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

Review 7.  Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis.

Authors:  Josep Mercader-Barceló; Joan Truyols-Vives; Carlos Río; Nora López-Safont; Ernest Sala-Llinàs; Alice Chaplin
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.